ArticleCancer reports (Hoboken, N.J.)2022

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia.

Courtney Samuels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.